NEW ORLEANS, Nov. 8, 2025 — A groundbreaking study presented at the American Heart Association’s Scientific Sessions 2025 in New Orleans has unveiled promising results for a new medication, DR10624, which significantly reduces triglyceride levels in patients with severe hypertriglyceridemia. The trial, which lasted 12 weeks, demonstrated a reduction of triglyceride levels by more than 60% in most participants.
The trial aimed to assess the safety and efficacy of DR10624, targeting patients with triglyceride levels between 500-2,000 mg/dL, who are at increased risk of cardiovascular disease and pancreatitis. The study’s findings suggest that DR10624 could become a vital treatment option for these patients, especially as current medications often fall short.
Mechanism and Impact of DR10624
DR10624 is unique in its approach, as it activates three different receptors: FGF21, glucagon, and GLP-1. These receptors play crucial roles in the body’s management of fats and sugars. This multi-target approach is the first of its kind, potentially offering a comprehensive treatment for lipid disorders.
“DR10624 could become a game-changer for patients with severe hypertriglyceridemia by reducing long-term risks of pancreatitis, as well as conditions like MASLD and cardiovascular disease,” said lead study author Jianping Li, M.D., Ph.D.
The study involved 79 adults with severe hypertriglyceridemia, who were randomly assigned to receive either DR10624 or a placebo. Remarkably, 89.5% of those treated with DR10624 achieved triglyceride levels below 500 mg/dL, compared to just 25% of the placebo group.
Significant Reductions in Liver Fat
In addition to lowering triglyceride levels, DR10624 also showed a 63.5% reduction in liver fat among participants, a critical outcome since excess liver fat is common in patients with high triglycerides. This reduction is particularly important as it addresses metabolic dysfunction-associated steatotic liver disease (MASLD), a condition with limited treatment options.
Patients also experienced improvements in other lipid measures, including total cholesterol and high-density lipoprotein cholesterol. However, gastrointestinal issues such as nausea were noted as common side effects, a typical response to medications targeting GLP-1 receptors.
Study Design and Limitations
The study was conducted with a double-blind design, ensuring neither participants nor researchers knew who received the medication versus the placebo. Despite its promising results, the study’s short duration and limited participant diversity are notable limitations. The trial included primarily Asian men, and the findings may not be generalizable to broader populations.
The study had several limitations, including the short duration of the treatment period of only 12 weeks. More research is needed to understand if DR10624 continues to work well with a longer duration of treatment.
Furthermore, DR10624 was not directly compared to other triglyceride-lowering medications, leaving questions about its relative efficacy and safety unanswered.
Future Directions and Implications
The researchers emphasize the need for longer-term studies with diverse populations to fully understand DR10624’s potential. Future trials could explore its use in combination with other medications, such as glucose-lowering drugs, to enhance metabolic control in patients with conditions like Type 2 diabetes and obesity.
“Given that DR10624 targets multiple metabolic pathways simultaneously, it could be a strong candidate for combination therapies with other medications,” said Li.
The development of DR10624 represents a significant advancement in the treatment of severe hypertriglyceridemia, offering hope for improved patient outcomes and quality of life. As research continues, this medication could redefine standard care practices for lipid disorders.
